Thioridazine combined with carboplatin results in synergistic inhibition of triple negative breast cancer by targeting cancer stem cells
Open Access
- 30 September 2022
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 26, 101549
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Dopamine enhances the response of sunitinib in the treatment of drug-resistant breast cancer: Involvement of eradicating cancer stem-like cellsBiochemical Pharmacology, 2015
- Breast cancer stem cells: Multiple capacities in tumor metastasisCancer Letters, 2014
- Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancerOncology Reports, 2014
- Characterization of a Novel Transgenic Mouse Tumor Model for Targeting HER2+ Cancer Stem CellsInternational Journal of Biological Sciences, 2014
- A Phase II Trial of Docetaxel and Carboplatin Administered Every 2 Weeks as Preoperative Therapy for Stage II or III Breast CancerAmerican Journal of Clinical Oncology, 2013
- Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB PatientPharmaceuticals, 2012
- Identification of Drugs Including a Dopamine Receptor Antagonist that Selectively Target Cancer Stem CellsCell, 2012
- Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cellsApoptosis, 2012
- Targeting ALDHbright Human Carcinoma–Initiating Cells with ALDH1A1-Specific CD8+ T CellsClinical Cancer Research, 2011
- Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast CancersClinical Cancer Research, 2009